Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

BioNTech (BNTX) recently witnessed a 13.9% increase in its share price over the last quarter. This period saw significant executive changes, including the upcoming departure of Chief Strategy Officer ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, ...

BioNTech SE(Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the Company will host a conference call ...

The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies.

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

Bristol Myers Squibb (BMY) ended the recent trading session at $48.02, demonstrating a +2.85% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a ...

The exanthema market is projected to grow from USD 1.39 billion in 2024 to USD 2.51 billion by 2034 at a CAGR of 6.10%. This growth is driven by risi ...

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...